3-甲基-5-三氟甲基苯乙酸 | 1214352-00-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲基-5-三氟甲基苯乙酸
• 中文别名: 2-(3-甲基-5-(三氟甲基)苯基)乙酸
• 英文名称: 2-(3-Methyl-5-(trifluoromethyl)phenyl)acetic acid
• 英文别名: 2-[3-methyl-5-(trifluoromethyl)phenyl]acetic acid
• CAS: 1214352-00-7
• 化学式: C₁₀H₉F₃O₂
• 分子量: 218.17
• InChiKey: ZRKPLBYMYLSCBD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] SULFONAMIDE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE SULFONAMIDE ET LEURS UTILISATIONS
  申请人：NODTHERA LTD

  公开号：WO2020249669A1

  公开（公告）日：2020-12-17

  The present disclosure relates to compounds of Formula (I) or (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

  本公开涉及式（I）或（II）的化合物，以及它们的前药、药用盐、药物组合物、使用方法和制备方法。本文披露的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗涉及炎症小体活性的疾病，如炎症性、自身免疫性和自身免疫性疾病以及癌症。
• INHIBITORS OF CYTOMEGALOVIRUS
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20150284348A1

  公开（公告）日：2015-10-08

  Compounds of Formula (I) wherein n, R 1 , R 1A , R 2 , R 4 and Z are defined herein, are useful for the treatment of cytomegalovirus disease and/or infection.
• SULFONAMIDE DERIVATIVES AND USES THEREOF
  申请人：NodThera Limited

  公开号：US20220267300A1

  公开（公告）日：2022-08-25

  The present disclosure relates to compounds of Formula (I) or (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.
• US9334249B2
  申请人：——

  公开号：US9334249B2

  公开（公告）日：2016-05-10
• [EN] NEK7 INHIBITORS<br/>[FR] INHIBITEURS DE NEK7
  申请人：[en]HALIA THERAPEUTICS, INC.

  公开号：WO2022212326A1

  公开（公告）日：2022-10-06

  Compounds having activity as inhibitors of NEK7 are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein A, X, Y, R1, R2, R3, R4, R5, R6, R7, and R8are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to treat diseases or disorders (e.g., cancer) are also provided.